What are the latist stats on nsclc survival and stage especially early stage

Portal Forums Q&A, Ask Us New Questions What are the latist stats on nsclc survival and stage especially early stage

This topic contains 4 replies, has 3 voices, and was last updated by  onthemark 3 weeks, 1 day ago.

Viewing 5 posts - 1 through 5 (of 5 total)
Author Posts   
Author Posts
May 1, 2018 at 10:18 am  #1294343    

metafran

Hi,
I have been reading through the articles etc of this site. What a great place to get good info. Thanks to the team.
My question deals with the survival of nsclc in early stage including interventions as I am trying to find an up to date one.
Thanks

May 1, 2018 at 11:12 am  #1294344    

onthemark

The latest large scale data analysis I know of is in the 2016 publicly available paper
Journal of Thoracic Oncology, Vol. 11, Issue 1, January 2016, Pages 39-51

“The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer”

I tried to drag parts of Figure 3, which has the survival data by detailed stage, and post it here, but i am not sure how to post figures. Pay attention to the long term survival data on the right hand side of Figure 3. The left hand side is the same data but classified according to the (old) 7th edition.

The database contains cases that were treated using all modalities of care, including multimodality treatment, and diagnosed between 1999 and 2010. For the analyses of TNM categories presented here, only cases with a histologic diagnosis of non–small cell lung cancer and complete staging information were included. For cases in which chemotherapy was received before surgery (yp cases), only clinical stage was considered…

Survival was measured from the date of diagnosis for clinically staged tumors and from the date of surgery for pathologically staged tumors and calculated by the Kaplan-Meier method. Adjusted survival curves21,22 were drawn using inverse probability weights applied to the survival calculations on the basis of the proportion of cases that were from registry databases (versus others) in each stage category. This method was used in light of the different overall survival prognosis in registry databases in general, combined with the disproportionate representation of registry cases in some of the stage groups.

One can expect actual long term survival now to be higher because of the new treatment modalities that have been developed in the mean time. Also, it is a pretty complex calculation they used to get their curves.

https://www.sciencedirect.com/science/article/pii/S1556086415000179


10/2015 Chest xray found a nodule as part of a physical (no symptoms).
01/2016 Upper left lobe lingula preserving lobectomy stage 2b for 1.9 cm invasive adenocarcinoma with additional 2 mm AIS nodule found in pathology.
03-05/2016 Sixteen weeks of adjuvant cisplatin/vinorelbine.
07/2016 Durvalumab adjuvant clinical trial discontinued after 1st dose knocked out thyroid.
12/2016 Revised to stage 1b (due to VPI) after new guidelines for multifocal lepidic lung cancer.
07/2018 Next scan.

  • This reply was modified 3 weeks, 1 day ago by  onthemark.
  • This reply was modified 3 weeks, 1 day ago by  onthemark.
May 1, 2018 at 12:46 pm  #1294347    
catdander forum moderator
catdander forum moderator

A good preface to read about prognosis and the individual from https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html “Survival rates don’t tell the whole story
Survival rates are often based on previous outcomes of large numbers of people who had the disease, but they can’t predict what will happen in any particular person’s case. There are a number of limitations to keep in mind:

“The numbers below are among the most current available. But to get 5-year survival rates, doctors have to look at people who were treated at least 5 years ago. As treatments are improving over time, people who are now being diagnosed with non-small cell lung cancer (NSCLC) may have a better outlook than these statistics show.
These statistics are based on the stage of the cancer when it was first diagnosed. They do not apply to cancers that later come back or spread, for example.
The outlook for people with NSCLC varies by the stage (extent) of the cancer – in general, the survival rates are higher for people with earlier stage cancers. But many other factors can affect a person’s outlook, such as the subtype of NSCLC, gene changes in the cancer cells, the person’s age and overall health, and how well the cancer responds to treatment. The outlook for each person is specific to his or her circumstances.
Your doctor can tell you how these numbers may apply to you, as he or she is familiar with your particular situation.”

Cont’d

May 1, 2018 at 12:54 pm  #1294348    
catdander forum moderator
catdander forum moderator

…”Survival rates for non-small cell lung cancer, by stage
The numbers below come from thousands of people from all over the world who were diagnosed with NSCLC between 1999 and 2010. Although the numbers are based on people diagnosed several years ago, they are the most recent rates published for the current AJCC staging system.

“These survival rates include people who die from causes other than cancer.

“The 5-year survival rate for people with stage IA1 NSCLC is about 92%. For people with stage IA2 NSCLC, the 5-year survival rate is about 83%. For people with stage IA3 NSCLC, the 5-year survival rate is about 77%.
The 5-year survival rate for people with stage IB NSCLC is about 68%.
For stage IIA cancer, the 5-year survival rate is about 60%. For stage IIB cancer, the survival rate is about 53%.
The 5-year survival rate for stage IIIA NSCLC is about 36%. For stage IIIB cancers the survival rate is about 26%. For stage IIIC cancers the survival rate is about 13%.
NSCLC that has spread to other parts of the body is often hard to treat. The 5-year survival rate for stage IVA NSCLC is about 10%, and for stage IVB the 5-year survival rate is less than 1%. Still, there are often many treatment options available for people with these stages of cancer.
Remember, these survival rates are only estimates – they can’t predict what will happen to any individual person. We understand that these statistics can be confusing and may lead you to have more questions. Talk to your doctor to better understand your specific situation.”

I hope this adds something to onthemark’s answer. If you’re new to cancer it may take some time to understand how prognostic statistics don’t give very much for the individual to hang a hat on.

All best,
Janine

May 1, 2018 at 1:03 pm  #1294349    

onthemark

All the caveats that Janine posted are important to take into account.
The numbers Janine posted correspond to Figure 2 in the
Paper I linked to rather than Figure 3. I’m not able to explain
The difference between how these two Figures were
Obtained. I would look therefore at Fig 2 rather than 3 in order
To be consistent.


10/2015 Chest xray found a nodule as part of a physical (no symptoms).
01/2016 Upper left lobe lingula preserving lobectomy stage 2b for 1.9 cm invasive adenocarcinoma with additional 2 mm AIS nodule found in pathology.
03-05/2016 Sixteen weeks of adjuvant cisplatin/vinorelbine.
07/2016 Durvalumab adjuvant clinical trial discontinued after 1st dose knocked out thyroid.
12/2016 Revised to stage 1b (due to VPI) after new guidelines for multifocal lepidic lung cancer.
07/2018 Next scan.

Viewing 5 posts - 1 through 5 (of 5 total)

You must be logged in to reply to this topic.